R270C polymorphism leads to loss of function of the canine P2X7 receptor

Physiological Genomics

Volumn 46, Issue 14, 2014, Pages 512-522

  Spildrejorde, Mari ^a,b   Bartlett, Rachael ^a,b   Stokes, Leanne ^c,d   Jalilian, Iman ^a,b   Peranec, Michelle ^a,b   Sluyter, Vanessa ^a,b   Curtis, Belinda L ^e   Skarratt, Kristen K ^d   Skora, Amanda ^a,b   Bakhsh, Tahani ^a,b   Seavers, Aine ^f   McArthur, Jason D ^a,b   Dowton, Mark ^a,b   Sluyter, Ronald ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b ILLAWARRA HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c RMIT UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Albion Park Veterinary Hospital   (Australia)

^f Oak Flats Veterinary Clinic   (Australia)

Author keywords

Dog; Missense mutation; Monocyte; Purinergic receptor; Single nucleotide polymorphism

Indexed keywords

DYE; GENOMIC DNA; PURINERGIC P2X7 RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DOG BREED; EMBRYO; FLOW CYTOMETRY; GENETIC CODE; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; LABRADOR RETRIEVER; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; MONOCYTE; NONHUMAN; PATCH CLAMP TECHNIQUE; POINT MUTATION; PRIORITY JOURNAL; RANDOM SAMPLE; SITE DIRECTED MUTAGENESIS; ANIMAL; CELL LINE; DOG; GENETICS; HEK293 CELL LINE; HETEROZYGOTE; HOMOZYGOTE; MDCK CELL LINE; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CELL LINE; DOGS; HEK293 CELLS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MONOCYTES; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2X7;

EID: 84904279024     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.00195.2013     Document Type: Article

References (54)

1. Adriouch S, Dox C, Welge V, Seman M, Koch-Nolte F, Haag F. Cutting edge: a natural P451L mutation in the cytoplasmic domain impairs the function of the mouse P2X7 receptor. J Immunol 169: 4108-4112, 2002.
2. Amoroso F, Falzoni S, Adinolfi E, Ferrari D, Di Virgilio F. The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis 3: e370, 2012.
3. Awano T, Johnson GS, Wade CM, Katz ML, Johnson GC, Taylor JF, Perloski M, Biagi T, Baranowska I, Long S, March PA, Olby NJ, Shelton GD, Khan S, O'Brien DP, Lindblad-Toh K, Coates JR. Genome-wide association analysis reveals a SOD1 mutation in canine degenerative myelopathy that resembles amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 106: 2794-2799, 2009.
4. Barbera-Cremades M, Baroja-Mazo A, Gomez AI, Machado F, Di Virgilio F, Pelegrin P. P2X7 receptor-stimulation causes fever via PGE2 and IL-1beta release. FASEB J 26: 2951-2962, 2012.
5. Bartlett R, Yerbury JJ, Sluyter R. P2X7 receptor activation induces reactive oxygen species formation and cell death in murine EOC13 microglia. Mediators Inflamm 2013: 271813, 2013.
6. Beaucage KL, Xiao A, Pollmann SI, Grol MW, Beach RJ, Holdsworth DW, Sims SM, Darling MR, Dixon SJ. Loss of P2X7 nucleotide receptor function leads to abnormal fat distribution in mice. Purinergic Signal 10: 291-304, 2014.
7. Bhaskaracharya A, Dao-Ung P, Jalilian I, Spildrejorde M, Skarratt KK, Fuller SJ, Sluyter R, Stokes L. Probenecid blocks human P2X7 receptor-induced dye uptake via a pannexin-1 independent mechanism. PLoS One 9: e93058, 2014.
8. Boudreaux MK, Martin M. P2Y12 receptor gene mutation associated with postoperative hemorrhage in a Greater Swiss Mountain dog. Vet Clin Pathol 40: 202-206, 2011.
9. Boyko AR, Quignon P, Li L, Schoenebeck JJ, Degenhardt JD, Lohmueller KE, Zhao K, Brisbin A, Parker HG, vonHoldt BM, Cargill M, Auton A, Reynolds A, Elkahloun AG, Castelhano M, Mosher DS, Sutter NB, Johnson GS, Novembre J, Hubisz MJ, Siepel A, Wayne RK, Bustamante CD, Ostrander EA. A simple genetic architecture underlies morphological variation in dogs. PLoS Biol 8: e1000451, 2010.
10. Bradley HJ, Browne LE, Yang W, Jiang LH. Pharmacological properties of the rhesus macaque monkey P2X7 receptor. Br J Pharmacol 164: 743-754, 2011.
11. Browne LE, Compan V, Bragg L, North RA. P2X7 receptor channels allow direct permeation of nanometer-sized dyes. J Neurosci 33: 3557-3566, 2013.
12. Chessell IP, Simon J, Hibell AD, Michel AD, Barnard EA, Humphrey PP. Cloning and functional characterisation of the mouse P2X7 receptor. FEBS Lett 439: 26-30, 1998.
13. Constantinescu P, Wang B, Kovacevic K, Jalilian I, Bosman GJ, Wiley JS, Sluyter R. P2X7 receptor activation induces cell death and microparticle release in murine erythroleukemia cells. Biochim Biophys Acta 1798: 1797-1804, 2010.
14. Denlinger LC, Coursin DB, Schell K, Angelini G, Green DN, Guadarrama AG, Halsey J, Prabhu U, Hogan KJ, Bertics PJ. Human P2X7 pore function predicts allele linkage disequilibrium. Clin Chem 52: 995-1004, 2006.
15. Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF. Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157: 1203-1214, 2009.
16. Dukes JD, Whitley P, Chalmers AD. The MDCK variety pack: choosing the right strain. BMC Cell Biol 12: 43, 2011.
17. Fernando SL, Saunders BM, Sluyter R, Skarratt KK, Goldberg H, Marks GB, Wiley JS, Britton WJ. A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. Am J Respir Crit Care Med 175: 360-366, 2007.
18. Gadeock S, Pupovac A, Sluyter V, Spildrejorde M, Sluyter R. P2X7 receptor activation mediates organic cation uptake into human myeloid leukaemic KG-1 cells. Purinergic Signal 8: 669-676, 2012.
19. Gargett CE, Cornish JE, Wiley JS. ATP, a partial agonist for the P2Z receptor of human lymphocytes. Br J Pharmacol 122: 911-917, 1997.
20. Gargett CE, Wiley JS. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol 120: 1483-1490, 1997.
21. Gartland A, Skarratt KK, Hocking LJ, Parsons C, Stokes L, Jorgensen NR, Fraser WD, Reid DM, Gallagher JA, Wiley JS. Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet 20: 559-564, 2012.
22. Gidlof O, Smith JG, Melander O, Lovkvist H, Hedblad B, Engstrom G, Nilsson P, Carlson J, Berglund G, Olsson S, Jood K, Jern C, Norrving B, Lindgren A, Erlinge D. A common missense variant in the ATP receptor P2X7 is associated with reduced risk of cardiovascular events. PLoS One 7: e37491, 2012.
23. Gu BJ, Saunders BM, Petrou S, Wiley JS. P2X7 is a scavenger receptor for apoptotic cells in the absence of its ligand, extracellular ATP. J Immunol 187: 2365-2375, 2011.
24. Gu BJ, Zhang WY, Worthington RA, Sluyter R, Dao-Ung P, Petrou S, Barden JA, Wiley JS. A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276: 11135-11142, 2001.
25. Jalilian I, Peranec M, Curtis BL, Seavers A, Spildrejorde M, Sluyter V, Sluyter R. Activation of the damage-associated molecular pattern receptor P2X7 induces interleukin-1 β release from canine monocytes. Vet Immunol Immunopathol 149: 86-91, 2012.
26. Jalilian I, Spildrejorde M, Seavers A, Curtis BL, McArthur JD, Sluyter R. Functional expression of the damage-associated molecular pattern receptor P2X7 on canine kidney epithelial cells. Vet Immunol Immunopathol 150: 228-233, 2012.
27. Jiang LH, Baldwin JM, Roger S, Baldwin SA. Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol 4: 55, 2013.
28. Jiang LH, Mackenzie AB, North RA, Surprenant A. Brilliant blue G selectively blocks ATP-gated rat P2X7 receptors. Mol Pharmacol 58: 82-88, 2000.
29. Jindrichova M, Kuzyk P, Li S, Stojilkovic SS, Zemkova H. Conserved ectodomain cysteines are essential for rat P2X7 receptor trafficking. Purinergic Signal 8: 317-325, 2012.
30. Kathrani A, House A, Catchpole B, Murphy A, German A, Werling D, Allenspach K. Polymorphisms in the TLR4 and TLR5 gene are significantly associated with inflammatory bowel disease in German shepherd dogs. PLoS One 5: e15740, 2010.
31. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, Delcher AL, Pop M, Wang W, Fraser CM, Venter JC. The dog genome: survey sequencing and comparative analysis. Science 301: 1898-1903, 2003.
32. Lester S, Stokes L, Skarratt K, Gu B, Silvils K, Lessard C, Wiley JS, Rischmueller M. Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary Sjögren's syndrome. Arthritis Res Ther 15: R71, 2013.
33. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, deJong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, DeCaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle SMJ, Sutter NB, Thomas R, Webber C, Broad Institute Sequencing Platform, Lander ES. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438: 803-819, 2005.
34. Michel AD, Chambers LJ, Walter DS. Negative and positive allosteric modulators of the P2X7 receptor. Br J Pharmacol 153: 737-750, 2008.
35. Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, Niforatos W, Honore P, Jarvis MF, Faltynek CR, Carroll WA. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem 49: 3659-3666, 2006.
36. North RA, Jarvis MF. P2X receptors as drug targets. Mol Pharmacol 83: 759-769, 2013.
37. Parker JC, Snow RL. Influence of external ATP on permeability and metabolism of dog red blood cells. Am J Physiol 223: 888-893, 1972.
38. Pupovac A, Foster CM, Sluyter R. Human P2X7 receptor activation induces the rapid shedding of CXCL16. Biochem Biophys Res Commun 432: 626-631, 2013.
39. Pupovac A, Stokes L, Sluyter R. CAY10593 inhibits the human P2X7 receptor independently of phospholipase D1 stimulation. Purinergic Signal 9: 609-619, 2013.
40. Qu Y, Franchi L, Nunez G, Dubyak GR. Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J Immunol 179: 1913-1925, 2007.
41. Rassendren F, Buell G, Newbolt A, North RA, Surprenant A. The permeabilizing ATP receptor, P2X7. Cloning and expression of human cDNA. J Biol Chem 272: 5482-5486, 1997.
42. Roman S, Cusdin FS, Fonfria E, Goodwin JA, Reeves J, Lappin SC, Chambers L, Walter DS, Clay WC, Michel AD. Cloning and pharmacological characterization of the dog P2X7 receptor. Br J Pharmacol 158: 1513-1526, 2009.
43. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung WY, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, Brown Jr H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62, 1993.
44. Sluyter R, Shemon AN, Hughes WE, Stevenson RO, Georgiou JG, Eslick GD, Taylor RM, Wiley JS. Canine erythrocytes express the P2X7 receptor: greatly increased function compared with human erythrocytes. Am J Physiol Regul Integr Comp Physiol 293: R2090-R2098, 2007.
45. Sluyter R, Stokes L. Significance of P2X7 receptor variants to human health and disease. Recent Pat DNA Gene Seq 5: 41-54, 2011.
46. Spadafora D, Hawkins EC, Murphy KE, Clark LA, Ballard ST. Naturally occurring mutations in the canine CFTR gene. Physiol Genomics 42: 480-485, 2010.
47. Spildrejorde M, Curtis SJ, Curtis BL, Sluyter R. Extracellular adenosine 5'-triphosphate and lipopolysaccharide induce interleukin-1β release in canine blood. Vet Immunol Immunopathol 157: 105-110, 2014.
48. Stevenson RO, Taylor RM, Wiley JS, Sluyter R. The P2X7 receptor mediates the uptake of organic cations in canine erythrocytes and mononuclear leukocytes: comparison to equivalent human cell types. Purinergic Signal 5: 385-394, 2009.
49. Stokes L, Fuller SJ, Sluyter R, Skarratt KK, Gu BJ, Wiley JS. Two haplotypes of the P2X7 receptor containing the Ala-348 to Thr polymorphism exhibit gain-of-function effect and enhanced interleukin-1 β secretion. FASEB J 24: 2916-2927, 2010.
50. Stokes L, Jiang LH, Alcaraz L, Bent J, Bowers K, Fagura M, Furber M, Mortimore M, Lawson M, Theaker J, Laurent C, Braddock M, Surprenant A. Characterization of a selective and potent antagonist of human P2X7 receptors, AZ11645373. Br J Pharmacol 149: 880-887, 2006.
51. Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science 272: 735-738, 1996.
52. Syberg S, Petersen S, Beck Jensen JE, Gartland A, Teilmann J, Chessell I, Steinberg TH, Schwarz P, Jørgensen NR. Genetic background strongly influences the bone phenotype of P2X7 receptor knockout mice. J Osteoporos 2012: 391097, 2012.
53. Vonholdt BM, Pollinger JP, Lohmueller KE, Han E, Parker HG, Quignon P, Degenhardt JD, Boyko AR, Earl DA, Auton A, Reynolds A, Bryc K, Brisbin A, Knowles JC, Mosher DS, Spady TC, Elkahloun A, Geffen E, Pilot M, Jedrzejewski W, Greco C, Randi E, Bannasch D, Wilton A, Shearman J, Musiani M, Cargill M, Jones PG, Qian Z, Huang W, Ding ZL, Zhang YP, Bustamante CD, Ostrander EA, Novembre J, Wayne RK. Genome-wide SNP and haplotype analyses reveal a rich history underlying dog domestication. Nature 464: 898-902, 2010.
54. Wiley JS, Sluyter R, Gu BJ, Stokes L, Fuller SJ. The human P2X7 receptor and its role in innate immunity. Tissue Antigens 78: 321-332, 2011.